Citius Transnet Investment Trust IPO closed its bidding window on April 21, 2026. The allotment process is expected to be finalised tomorrow on April 24, 2026 with the shares set to be listed on both BSE and NSE . The tentative listing date is scheduled for April 29, 2026.
Citius Transnet Investment Trust operates in the transportation sector, with a primary focus on road infrastructure in India. It invests in and manages a portfolio of toll and annuity-based road projects through a network of special purpose vehicles (SPVs) and holding entities.
Explore other Upcoming IPOs on BSE and NSE.
Citius Transnet Investment Trust IPO was a book-building issue of ₹1,105.00 crores, consisting entirely of a fresh issue of 11.05 crore shares. The price band was set between ₹99 to ₹100 per share and the minimum lot size was 150. The minimum amount of investment for an application was ₹14,850.
Axis Capital Limited, Ambit Private Limited and ICICI Securities Limited were the book-running lead managers for the issue. KFin Technologies Limited was the registrar.
[April 21, 2026, 05:00 P.M]
|
Investor Category |
Subscription (Times) |
|
Institutional Investors |
23.21 |
|
Other Investors |
17.09 |
|
Total |
20.43 |
As per media reports, the Grey Market Premium (GMP) for Citius Transnet Investment Trust is reported to be ₹₹3.5.
Citius TransNet Investment Trust (InvIT) is a transport-focused infrastructure investment trust established to acquire, manage, and invest in road infrastructure assets across India. The trust primarily owns and operates a diversified portfolio of road assets, including toll-based and annuity-based highway projects, aimed at generating stable cash flows. Its initial portfolio comprises 10 road projects (7 toll and 3 annuity assets) spanning over 3,400 lane kilometres across multiple states in India, supported by an experienced operational team.
Financially, it reported revenue of around ₹2,165.62 crore in FY25, up from ₹2,038.53 crore in FY24, indicating steady growth in operational income.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.